Agenus Inc AGEN:NASDAQ

Last Price$2.92NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.90 (15)
Ask (Size)$2.97 (10)
Day Low / HighN/A - N/A
Volume4.4 M
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Agenus Inc ( NASDAQ )

Price: $2.92
Change: -0.10 (3.31%)
Volume: 4.4 M
4:00PM ET 12/03/2021
 
 

Stoke Therapeutics Inc ( NASDAQ )

Price: $20.31
Change: -3.54 (14.84%)
Volume: 1.0 M
4:00PM ET 12/03/2021
 
 

Precigen Inc ( NASDAQ )

Price: $3.67
Change: -0.32 (8.02%)
Volume: 1.7 M
4:00PM ET 12/03/2021
 
 

MiMedx Group Inc ( NASDAQ )

Price: $6.81
Change: -0.17 (2.44%)
Volume: 481.4 K
4:00PM ET 12/03/2021
 
 

MeiraGTx Holdings PLC ( NASDAQ )

Price: $17.54
Change: -0.98 (5.29%)
Volume: 161.5 K
4:00PM ET 12/03/2021
 

Read more news Recent News

Agenus Swings to Q3 Earnings as Revenue Increases; Shares Rise Pre-Bell
8:49AM ET 11/09/2021 MT Newswires

Agenus (AGEN) on Tuesday swung to Q3 earnings of $0.72 per share from a loss of $0.28 per share a year earlier. Three analysts polled by Capital IQ...

Update: Agenus to Withdraw Biologics License Application for Cervical Cancer Drug Candidate; Shares Slump
2:07PM ET 10/22/2021 MT Newswires

(Updates with share price in second paragraph) Agenus (AGEN) said Friday that it is withdrawing its biologics license application for cervical cancer drug...

Agenus to Withdraw Biologics License Application for Cervical Cancer Drug Candidate; Shares Fall Pre-Bell
9:22AM ET 10/22/2021 MT Newswires

Agenus (AGEN) said Friday it is withdrawing its biologics license application for cervical cancer drug candidate balstilimab at the recommendation of the...

Agenus to Receive $20 Million Payment from Bristol Myers Squibb for AGEN1777; Shares Up Pre-Bell
9:19AM ET 10/12/2021 MT Newswires

Agenus (AGEN) said Tuesday it has triggered a $20 million cash payment under its global licensing agreement with Bristol Myers Squibb (BMY) for AGEN1777 to...

Company Profile

Business DescriptionAgenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA. View company web site for more details
Address3 Forbes Road
Lexington, Massachusetts 02421-7305
Phone+1.781.674.4400
Number of Employees294
Recent SEC Filing11/12/2021S-3ASR
Chairman & Chief Executive OfficerGaro H. Armen
President & Chief Operating OfficerJennifer S. Buell
Chief Financial & Accounting Officer, VP-FinanceChristine M. Klaskin
Chief Technology OfficerMarc van Dijk

Company Highlights

Price Open$3.01
Previous Close$3.02
52 Week Range$2.50 - 6.79
Market Capitalization$749.9 M
Shares Outstanding256.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/21/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.10
Beta vs. S&P 500N/A
Revenue$36.8 M
Net Profit Margin1.30%
Return on Equity-3.00%

Analyst Ratings as of 11/18/2019

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset